United Kingdom · Question · Written question
UIN 13136
Idiopathic Hypersomnia: Drugs
Introduced
5 February 2024
Last action
13 February 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
13 February 2024
Summary
To ask the Secretary of State for Health and Social Care, if she will make an estimate of when the approval process for the use of Xywav to treat idiopathic hypersomnia will be completed.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
5 February 2024
Written question
To ask the Secretary of State for Health and Social Care, if she will make an estimate of when the approval process for the use of Xywav to treat idiopathic hypersomnia will be completed.
Source: Commons
13 February 2024
Answer
The Medicines and Healthcare products Regulatory Agency (MHRA) has not issued a marketing authorisation (MA) for Xywav. Should a MA application be received, the MHRA has procedures in place to review it, such as the 150 Day National procedure or the Inter...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-02-05/13136
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1687536
- uk · wq-1687536 · source updated 13 February 2024